Supplementary analyses to topline Phase II results reveal additional RP101 clinical strengths
· RP101 demonstrates treatment difference versus control (Intelligel vehicle) in inferior corneal staining with robust and significant improvement · SANDE symptom score also reveals significant treatment difference versus control in a subgroup of more severe patients · Both inferior corneal staining and SANDE endpoints have been accepted by the US FDA for clinical endpoints in other dry eye programs · RP101 is well-positioned for continued development in a larger pivotal clinical trial (December 29, 2020, Stockholm, Sweden) - After publishing topline Phase II results of the RP101